CYFIRMA Report Tracks India Healthcare Threat Activity, With Pharma Claims Unconfirmed
Summary
CYFIRMA’s 2026 report logs 20 India healthcare ransomware entries for Jan–Aug, including three pharma/biotech entries, and frequent data-exposure observations. Claims remain unverified; the report finds no evidence of a coordinated campaign targeting Indian pharma.
Key points
- CYFIRMA recorded 20 ransomware victim entries associated with India’s healthcare sector for January–August 2026; three were classified as Pharmaceuticals and Biotechnology. Listings alone do not establish compromise, exfiltration, or operational impact.
- For March–August 2026, the monitoring dataset recorded 28 data-breach observations, 20 data-leak observations, and 12 web-exploit observations. Records may overlap and are not independently confirmed incidents or unique victims.
- APT-associated group appearances in the dataset do not prove direct targeting or compromise. The report says it found no evidence of a coordinated geopolitical campaign specifically targeting Indian pharmaceutical organisations.
- Dark-web and Telegram observations include claims involving pharmacy and healthcare-professional data. The report says dataset authenticity, claimed record counts, and actual exposure remain unverified; some sample data also casts doubt on a seller’s description.
- The vulnerability list includes CVE-2023-43208 for NextGen Healthcare Mirth Connect, identified as its only healthcare-specific product; the report says all listed vulnerabilities appear in the CISA Known Exploited Vulnerabilities Catalog.
- Recommendations include prioritizing exposed and actively exploited vulnerabilities, phishing-resistant MFA, isolated and tested backups, least-privilege access, network segmentation, supplier reviews, and validating claims before treating them as confirmed incidents.
Article Details
- Publisher
- CYFIRMA
- Report Period
- January–August 2026 for ransomware and dark-web/Telegram monitoring; March–August 2026 for APT and threat-category observations; June–August 2026 for vulnerabilities; geopolitical reporting through mid-October 2026.
- Scope
- Monitoring and open-source assessment of cyber threats affecting India’s healthcare and pharmaceutical ecosystem, including ransomware entries, threat-category observations, APT-associated activity, dark-web and Telegram claims, vulnerabilities, and geopolitical exposure.
- Sample Size
- No single sample size; the report records 20 healthcare ransomware victim entries, while threat-category observations may overlap and are not independently confirmed incidents.
- Key Statistics
- January–August 2026: 20 ransomware victim entries were recorded for India’s healthcare sector; 3 were classified as Pharmaceuticals and Biotechnology (15%).
- March–August 2026: monitoring recorded 28 data-breach, 20 data-leak, 12 web-exploit, 10 claimed-hack, 4 hacktivism, and 1 DDoS observation; categories may overlap and are not independently verified.
- Healthcare ranked third in recorded ransomware victim entries, with 20, behind Information Technology (31) and Manufacturing (25) in the monitoring dataset.
- MISSION2074, Lazarus Group, and Cozy Bear each had 3 APT-associated observations in the March–August 2026 dataset; counts do not establish direct targeting or compromise.
- China accounted for approximately 73.7% of India’s imports of active pharmaceutical ingredients, bulk drugs, and drug intermediates in FY 2024–25, according to the Department of Pharmaceuticals.
- Recommendations
- Validate ransomware listings and advertised data-exposure claims before classifying them as confirmed incidents.
- Enforce phishing-resistant MFA, privileged-access controls, and monitoring for suspicious account activity.
- Prioritize remediation of internet-facing and business-critical vulnerabilities using verified asset information, vendor advisories, and the CISA KEV Catalog.
- Protect research, clinical-trial, manufacturing, and commercial data with least-privilege access, network segmentation, monitoring, and isolated, tested backups.
- Review third-party and supplier access, monitor credible threat-intelligence sources, and validate findings before escalating them as confirmed incidents.
MITRE ATT&CK
T1102 · Web ServiceThe report describes abuse of trusted cloud services, including cloud storage and Microsoft 365, for command and control.T1566 · PhishingThe report describes spear-phishing in activity attributed to UAT-11587.T1574.002 · DLL Side-LoadingThe report describes DLL sideloading in activity attributed to UAT-11587.
CVE
Threat Actors
CCCN2101Identified by the report as a Chinese-speaking cybercrime threat actor and recorded in two APT-associated observations relevant to India’s healthcare sector; direct targeting or compromise is not established.Cozy BearRecorded in three APT-associated observations tagged as relevant to India’s healthcare sector; the report says the count does not establish direct targeting or compromise.Fatemiyoun Electronic TeamPublished a Telegram post claiming to have compromised an Indian medical institution and accessed records and systems; the claim remains unverified and did not identify a pharmaceutical company.GLOBAL SECRET GROUPIdentified in ransomware victim entries classified as relevant to pharmaceutical-sector organisations; a listing alone does not confirm compromise, exfiltration, or operational impact.KrybitIdentified in ransomware victim entries classified as relevant to pharmaceutical-sector organisations; a listing alone does not confirm compromise, exfiltration, or operational impact.Lazarus GroupRecorded in three APT-associated observations tagged as relevant to India’s healthcare sector; the report also notes prior targeting of pharmaceutical and vaccine developers, but does not establish direct targeting of Indian pharmaceutical organisations during this period.MISSION2074Recorded in three APT-associated observations tagged as relevant to India’s healthcare sector during March–August 2026; the report says this does not establish direct targeting or compromise.Mustang PandaResearchers reportedly observed campaigns targeting India’s hydropower sector and government entities in June 2026; the report does not describe targeting of Indian pharmaceutical organisations.OilRigRecorded in two APT-associated observations tagged as relevant to India’s healthcare sector; the report says the observations do not prove direct targeting or compromise.SHORE CASTLERecorded in two APT-associated observations tagged as relevant to India’s healthcare sector; the report says the observations do not prove direct targeting or compromise.UAT-11587Described publicly as a China-nexus cluster using the Antino backdoor against government and policy organisations across Asia, including India; the report does not show targeting of Indian pharmaceutical organisations.
Malware
Vendors
MicrosoftThe reported tradecraft (spear-phishing, DLL sideloading, and abuse of trusted cloud services for command and control, including an Indian cloud storage service and Microsoft 365) is likely to be reused.NextGen HealthcareCVE-2023-43208 (NextGen Healthcare Mirth Connect) is the only healthcare-specific product in the list and merits priority review by organisations that operate the platform.
Products
Microsoft 365 Apps for EnterpriseThe reported tradecraft (spear-phishing, DLL sideloading, and abuse of trusted cloud services for command and control, including an Indian cloud storage service and Microsoft 365) is likely to be reused.Mirth ConnectCVE-2023-43208 (NextGen Healthcare Mirth Connect) is the only healthcare-specific product in the list and merits priority review by organisations that operate the platform.
Countries
ChinaSeparately, India’s Department of Pharmaceuticals reported in February 2026 that China accounted for approximately 73.7% of India’s imports of active pharmaceutical ingredients (APIs), bulk drugs, and drug intermediatesIndiaINDIA HEALTHCARE (PHARMA) INDUSTRY THREAT LANDSCAPE REPORT 2026Iranpharmaceutical and vaccine developers for intellectual property and revenue generation; Russia- and Iran-linked groups conduct broad espionage and, in some cases, disruptive operations against government,North KoreaNorth Korea-linked activity is relevant to the sector because Lazarus Group has previously targeted pharmaceutical and vaccine developers for intellectual property and revenue generation; Russia- and Iran-linked groupsPakistanPakistan-linked clusters have also historically targeted Indian government and health-related entities.Russiatargeted pharmaceutical and vaccine developers for intellectual property and revenue generation; Russia- and Iran-linked groups conduct broad espionage and, in some cases, disruptive operations against